Acumen Pharmaceuticals (ABOS) Return on Capital Employed (2021 - 2026)
Acumen Pharmaceuticals (ABOS) posted Return on Capital Employed of 115.77% for Q1 2026, up 4.16% sequentially from 120.79% in Q4 2025, and down 5322.0% YoY from 2.22% in Q1 2025.
Acumen Pharmaceuticals (ABOS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Return on Capital Employed for 6 years, with the latest figure at 115.77% in Q1 2026.
- Quarterly Return on Capital Employed fell 5322.0% year-over-year to 115.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 115.77% (down 5322.0% YoY) and the FY2025 annual result came in at 82.06%, down 3589.0% from the prior year.
- Return on Capital Employed climbed to 115.77% in Q1 2026 per ABOS's latest filing, from 120.79% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 11.3% in Q1 2022 and troughed at 120.79% in Q4 2025.
- A 5-year average of 46.99% and a median of 27.43% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed soared 466 bps in 2024, then slumped 7020 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 23.55% in 2022, then grew by 9 bps to 21.43% in 2023, then plunged by 136 bps to 50.59% in 2024, then sank by 139 bps to 120.79% in 2025, then climbed by 4 bps to 115.77% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 115.77%, 120.79%, and 102.31% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | Acumen Pharmaceuticals | 229.76 Mn | 229.76 Mn | - | -135.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -135.20% |
| Mar 31, 2026 | -115.77% |
| Dec 31, 2025 | -120.79% |
| Sep 30, 2025 | -102.31% |
| Jun 30, 2025 | -88.16% |
| Mar 31, 2025 | -62.55% |
| Dec 31, 2024 | -50.59% |
| Sep 30, 2024 | -36.01% |
| Jun 30, 2024 | -27.43% |
| Mar 31, 2024 | -22.14% |
| Dec 31, 2023 | -21.43% |
| Sep 30, 2023 | -25.20% |
| Jun 30, 2023 | -30.00% |
| Mar 31, 2023 | -26.80% |
| Dec 31, 2022 | -23.55% |
| Sep 30, 2022 | -19.62% |
| Jun 30, 2022 | -15.17% |
| Mar 31, 2022 | -11.30% |
| Dec 31, 2021 | -8.61% |